Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute

Background/Aim: There are several treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) in the world. In recent years, the use of docetaxel, abiraterone, enzalutamide, and apalutamide has been used for mHSPC, but combined androgen blockade (CAB) therapy using first-generation an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:In Vivo
Main Authors: MIYAZAWA, YOSHIYUKI, SEKINE, YOSHITAKA, ARAI, SEIJI, OKA, DAISUKE, NAKAYAMA, HIROSHI, SYUTO, TAKAHIRO, NOMURA, MASASHI, KOIKE, HIDEKAZU, MATSUI, HIROSHI, SHIBATA, YASUHIRO, SUZUKI, KAZUHIRO
Formato: Artigo
Idioma:Inglês
Publicado em: International Institute of Anticancer Research 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7880762/
https://ncbi.nlm.nih.gov/pubmed/33402486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12268
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados